United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Bridgewater Associates LP

Bridgewater Associates LP increased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 384.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,755 shares of the biotechnology company's stock after purchasing an additional 49,003 shares during the quarter. Bridgewater Associates LP owned approximately 0.14% of United Therapeutics worth $22,130,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Townsquare Capital LLC purchased a new position in United Therapeutics during the 3rd quarter valued at about $426,000. Brooklyn Investment Group purchased a new position in United Therapeutics during the third quarter valued at approximately $33,000. FMR LLC raised its stake in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after buying an additional 314,004 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in United Therapeutics by 22.3% during the third quarter. Fisher Asset Management LLC now owns 6,305 shares of the biotechnology company's stock worth $2,259,000 after buying an additional 1,150 shares during the period. Finally, Daiwa Securities Group Inc. boosted its position in United Therapeutics by 26.1% during the 3rd quarter. Daiwa Securities Group Inc. now owns 4,119 shares of the biotechnology company's stock valued at $1,476,000 after acquiring an additional 852 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of analyst reports. Argus upped their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Finally, TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $370.86.

United Therapeutics Trading Up 0.3 %

Shares of UTHR stock traded up $1.13 during trading hours on Thursday, hitting $378.13. The company's stock had a trading volume of 323,202 shares, compared to its average volume of 457,791. The company has a 50 day moving average of $366.89 and a 200 day moving average of $334.15. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The stock has a market cap of $16.88 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the firm earned $5.38 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 7,785 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now owns 2,615 shares of the company's stock, valued at $947,597.55. This trade represents a 74.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 127,227 shares of company stock valued at $47,398,820. 11.90% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.